L’Agence nationale de sécurité du médicament et des produits de santé (ANSM) has issued a public health warning regarding the illegal online promotion of unverified stem cell therapies targeting severe conditions, including Alzheimer’s disease, Parkinson’s disease, and autism. According to regulatory findings reported by Doctissimo, these foreign-operated medical websites market experimental cell treatments directly to French patients without any robust scientific backing or regulatory approval.
Operating from Turkey, two specific entities—identified by health regulators as Liv Hospital and You StemCell—have become the focus of recent sanitary police measures deployed by French authorities. The targeted websites promote cellular interventions and associated exosomes for serious pathologies that sometimes lack satisfactory curative treatments. Regulators emphasize that these unauthorized offerings present a dual hazard to vulnerable patients, combining direct biological risks with the dangerous delay of established, evidence-based medical care.
Public health officials continue to stress the vital distinction between authorized clinical trials and commercial operations promising unproven cures. The promotion of regenerative medicine online often preys on the emotional vulnerability of families facing debilitating diagnoses, prompting vigilance and enforcement actions across digital platforms.
Targeting Incurable Pathologies Through Unverified Online Marketing
The digital platforms identified by the ANSM market cellular therapies for a broad spectrum of heavy, degenerative, and developmental disorders. According to Doctissimo, the advertised indications extend far beyond neurodegenerative conditions like Alzheimer’s and Parkinson’s disease. Promoted treatments also target cerebral palsy, multiple sclerosis, amyotrophic lateral sclerosis (commonly known as Charcot’s disease), diabetes, and infertility.
For patients and their families, navigating these claims can prove difficult when confronted with terminal or progressive illnesses. Commercial websites frequently utilize patient testimonials and presentations of innovative interventions to blur the line between legitimate scientific advancements and unproven therapies. Regulators note that these operations frame cellular treatments as transformative solutions, despite a complete absence of the rigorous clinical data required by European health standards.
Neither Liv Hospital nor You StemCell holds a marketing authorization (Autorisation de Mise sur le Marché, or AMM) issued in France or within the broader European Union. Under current regulatory frameworks, cellular therapies—whether administered alone or in combination with exosomes—fall under the legal definition of medicinal products. Consequently, distributing or promoting these substances without prior institutional evaluation violates public health laws designed to protect consumers from fraudulent medical claims.
The Double Hazard: Direct Health Risks and Loss of Chance
Health authorities warn that the dangers associated with unauthorized stem cell clinics extend beyond potential physical side effects or adverse biological reactions. Because these treatments bypass standard pre-market safety evaluations, patients do not benefit from the same guarantees as for a validated treatment regarding the quality, safety, or efficacy of the administered cellular products.
Furthermore, regulators highlight a more silent and insidious danger known as the “loss of chance” (perte de chance). When patients choose to pursue foreign experimental treatments advertised online, they may decide to halt, abandon, or delay proven therapeutic protocols prescribed by their primary medical teams. Postponing established care for unverified stem cell interventions can have consequences on the evolution of the disease.
To combat these unauthorized practices, the ANSM has initiated specific sanitary police measures aimed at restricting and suspending the digital promotion of these therapies within French territory. Public health bodies continue to urge patients, caregivers, and medical professionals to verify all treatment claims through official regulatory channels before considering medical travel abroad.
Regulatory Enforcement and Ongoing Patient Protection
The intervention against Liv Hospital and You StemCell marks an effort by health regulators to police cross-border medical advertising conducted via the internet. Digital accessibility allows foreign clinics to bypass domestic advertising restrictions, directly reaching patients across national borders who may be desperate for breakthrough treatments.
Individuals are encouraged to consult medical specialists and national health agencies before engaging with any clinic offering fee-based experimental procedures overseas. Official updates regarding banned health products, unauthorized medical websites, and ongoing safety advisories remain accessible directly through the ANSM official portal.
Authorities will continue monitoring online platforms for similar unverified medical claims, with further regulatory notifications and sanitary measures expected as investigations into illegal stem cell marketing develop.
Worth a look